Designing rigorous clinical trials for migraine therapies requires precise definitions, reliable tracking tools, and robust statistical endpoints
In clinical studies evaluating CGRP antagonists like telcagepant, trials strictly adhere to International Headache Society (IHS) diagnostic criteria
To translate this self-reported data into measurable metrics, researchers establish standardized definitions:
Headache Day: Any calendar day on which a headache lasting at least 30 minutes occurs, or any headache for which acute treatment is taken
. Migraine Day: A headache day accompanied by at least one classic associated symptom (aura, photophobia, phonophobia, nausea, or vomiting)
. Primary Efficacy Endpoints: The change from baseline in mean monthly headache days and mean monthly migraine days over a 12-week period
. Secondary Endpoints: The proportion of "responder" patients achieving a $\ge 50\%$ reduction in monthly headache/migraine days, as well as changes in monthly rescue medication usage
.
Statistical models utilize longitudinal data analysis to account for baseline variability and track changes month by month